New York — Investors who purchased securities from Edwards Lifesciences Corporation between February 6, 2024, and July 24, 2024, are potentially eligible for compensation, as announced by Rosen Law Firm, a global investor rights legal practice. The firm, which focuses on securities class actions and shareholder derivative litigation, has set a lead plaintiff deadline of December 13, 2024.
Anyone who acquired shares in Edwards Lifesciences during the said period might take part in the class action lawsuit without any out-of-pocket fees, as the costs are covered by a contingency fee arrangement. Those interested in joining the lawsuit or acting as the lead plaintiff, which involves representing other class members in the proceedings, should contact Phillip Kim, Esq. at 866-767-3653 or email pkim@rosenlegal.com for more information.
During the period in question, the lawsuit alleges that Edwards Lifesciences provided misleading information concerning the company’s revenue forecasts for 2024. This was particularly related to its Transcatheter Aortic Valve Replacement (TAVR) products. The company expressed strong expectations for market demand in various under-served areas and assured investors of its strategic initiatives to capture these markets. However, the suit claims that when truthful details regarding these projections came to light, it resulted in investor losses.
The Rosen Law Firm encourages investors to choose experienced and qualified counsel to represent them in securities class actions. Highlighting its expertise, the Rosen Law Firm has consistently ranked among the top firms for number of class action settlements. In 2017, it was ranked No. 1 by ISS Securities Class Action Services and has been in the top four since 2013. Notably, the firm secured over $438 million for investors in 2019 alone, marking its stance as a formidable presence in securities litigation.
Potential plaintiffs have until December 13, 2024, to apply to be appointed as lead plaintiff in the class action lawsuit. It is important to note that no class has yet been certified. Until such certification, investors are not represented by Rosen Law Firm unless they hire the firm or another attorney. Investors are free to retain counsel of their choice and may also choose to remain an absent class member, retaining the option to pursue recovery later if a class is certified.
Rosen Law Firm is headquartered in New York City at 275 Madison Avenue, where Laurence Rosen, Esq., founding partner and a notable figure in the plaintiffs’ bar, leads a skilled team dedicated to representing investors globally in securities matters.
Contact information for The Rosen Law Firm, including a toll-free number and email addresses for Laurence Rosen and Phillip Kim, is readily available for investors seeking legal advice or information regarding the class action suit.
Lastly, it is to be noted that outcomes of previous cases do not guarantee similar results in future lawsuits, consistent with standard attorney advertising disclaimers.
Please be aware that this article was automatically generated by Open AI and may contain inaccuracies. The people, facts, circumstances, and story reported might be incorrect. Corrections, retractions, or removal requests can be sent to contact@publiclawlibrary.org.